Warwick spinout to revolutionise AI for cellular pathology

A longstanding research collaboration between the University of Warwick and University Hospitals Coventry and Warwickshire has led to the development of exciting new technology which will speed up the diagnoses of cancer and improve treatment for cancer patients. 

Using artificial intelligence, the technology will analyse tissue samples from people with suspected cancer and accelerate diagnosis by functioning even when the pathologist is unavailable. The pioneering technology will enable automatic screening of normal samples so that pathologists can better use their resources and focus on those that show signs of cancer.

The scientific team of Prof Nasir Rajpoot and Dr Simon Graham (Department of Computer Science, University of Warwick) and Prof David Snead (consultant pathologist at University Hospital Coventry and Warwickshire) have been working with Warwick Innovations (University of Warwick) to form a spinout company, Histofy Ltd, that will further develop the technology into software that can be used in cancer labs throughout the world.

Tim Francis, Business Development Manager – Warwick Innovations said: “This is an important step in the realisation of technology developed through the research partnership between Warwick and UHCW. There is great potential for improvements in cancer treatment and patient outcomes.”

An Important Milestone

Birmingham, UK (2023.03.08) – Histofy, a medical technology company specialising in developing transparent AI models for pathology, has announced that it is now a spinout from the University of Warwick. The company’s technology aims to revolutionise tissue based research and practice by bringing AI technologies for deep tissue profiling to the market.

Histofy’s innovative technology brings avant-garde AI to histopathology and offers precise and accurate tissue profiling that will enable faster and more accurate diagnostics, prognostics and predictive analytics. With a focus on the clinical and biopharma markets, the company’s technology has the potential to improve patient outcomes and reduce healthcare costs.

The spinout from the University of Warwick marks an important milestone for Histofy, as it enables the company to develop and commercialise its innovative technology. The founding team of medical and AI experts is dedicated to driving innovation in the pathology field through the use of transparent AI models.

Prof Nasir Rajpoot, Chief Scientific Officer at Histofy, said: “I am excited for Histofy to pioneer the clinical translation of AI based biomarkers for improved diagnosis, prognosis and treatment selection. Our AI tools will leverage the huge amount of pathology data that exists worldwide and ultimately lead to faster diagnosis and better treatment”.

Prof David Snead, Chief Medical Officer at Histofy, stated: “I firmly believe in the tremendous potential of AI in pathology. The technology that Histofy is creating will transform the future of pathology, leading to more objective diagnosis, personalised medicine and shorter turnaround times”.

Histofy’s innovative technology has already gained recognition in the medical community, with the founding team publishing over 250 papers in esteemed journals. The spinout from the University of Warwick further strengthens the company’s position in the market, as it continues to explore new ways of tissue profiling.

Dr Simon Graham, Chief Technology Officer at Histofy, said:  “At Histofy we are looking forward to placing AI in the hands of biomedical researchers and practitioners to improve patient care. We are ready to make AI accessible across a range of solutions for the digital pathology market and believe that our technology will dramatically improve the management of complex diseases, such as cancer”.

For more information please contact:

Dr. Simon Graham, Histofy Ltd | +44 (0)7804104328

Or s.graham@histofy.ai

For more about Warwick Innovations click here: https://warwickinnovationdistrict.com/warwick-innovations/